NASDAQ: CRNXCrinetics Pharmaceuticals Inc Stock
$31.77-0.40 (-1.24%)
Updated Jun 13, 2025
CRNX Price
$31.77
Fair Value Price
$0.58
Market Cap
$2.98B
52 Week Low
$24.10
52 Week High
$62.53
P/E
-8.34x
P/B
2.37x
P/S
4,108.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$760.00k
Earnings
-$328.25M
Gross Margin
100%
Operating Margin
-43,191.05%
Profit Margin
-43,191.1%
Debt to Equity
0.09
Operating Cash Flow
-$262M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CRNX Overview
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRNX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CRNX
Ranked#339 of 464
Ranked#339 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important CRNX news, forecast changes, insider trades & much more!
CRNX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRNX ($31.77) is overvalued by 5,366.6% relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRNX ($31.77) is not significantly undervalued (5,366.6%) relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRNX due diligence checks available for Premium users.
Valuation
CRNX fair value
Fair Value of CRNX stock based on Discounted Cash Flow (DCF)
Price
$31.77
Fair Value
$0.58
Overvalued by
5,366.60%
CRNX ($31.77) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRNX ($31.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.34x
Industry
-108.97x
Market
31.36x
CRNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.37x
Industry
4.66x
CRNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRNX's financial health
Profit margin
Revenue
$361.0k
Net Income
-$96.8M
Profit Margin
-26,807.2%
CRNX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CRNX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.4B
Liabilities
$107.3M
Debt to equity
0.09
CRNX's short-term assets ($1.29B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRNX's short-term assets ($1.29B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRNX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$88.5M
Investing
-$86.0M
Financing
$4.4M
CRNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRNX vs Biotech Stocks
Crinetics Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.